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presentation to T cells, regulation of IgE responses, and
enhancement of transepithelial allergen migration.
Objective: We sought to investigate the interaction between
CD23, chimeric monoclonal human IgE, and the corresponding
birch pollen allergen Bet v 1 at a molecular level.
Methods: We expressed 4 CD23 variants. One variant
comprised the full extracellular portion of CD23, including the
stalk and head domain; 1 variant was identical with the first,
except for an amino acid exchange in the stalk region abolishing
the N-linked glycosylation site; and 2 variants represented the
head domain, 1 complete and 1 truncated. The 4 CD23 variants
were purified as monomeric and structurally folded proteins, as
demonstrated by gel filtration and circular dichroism. By using
a human IgE mAb, the corresponding allergen Bet v 1, and a
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electron microscopy were performed.
Results: A hitherto unknown IgE-binding site was mapped on the
stalk region of CD23, and the non–N-glycosylated monomeric
version of CD23 was superior in IgE binding compared with
glycosylated CD23. Furthermore, we demonstrated that a
therapeutic anti-IgE antibody, omalizumab, which inhibits IgE
binding to FcεRI, also inhibited IgE binding to CD23.
Conclusion: Our results provide a new model for the CD23-IgE
interaction. We show that the stalk region of CD23 is crucially
involved in IgE binding and that the interaction can be blocked
by the therapeutic anti-IgE antibody omalizumab. (J Allergy
Clin Immunol 2017;139:281-9.)
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IgE-associated allergy is the most frequent immunologically
mediated hypersensitivity disease, affectingmore than 25% of the
population worldwide.1 IgE is the least abundant immunoglob-
ulin class and therefore exerts its pathologic effects mainly
through interaction with 2 cellular receptors: the high-affinity
receptor FcεRI and the low-affinity receptor CD23 (FcεRII).2
The molecular and structural interaction between IgE and FcεRI
has been investigated in great detail3 and represents an important
target for therapeutic strategies for allergy.4-6
The interaction between IgE and the low-affinity receptorCD23
is less well understood than that between IgE and the high-affinity
receptor FcεRI, although CD23 plays several important roles in
allergic inflammation. CD23 is a key molecule in IgE-facilitated
allergen presentation and subsequent activation of allergen-
specific T cells,7 a mechanism that can be blocked by allergen-
specific IgG after specific immunotherapy.8 Furthermore, CD23
was suggested to be important in the regulation of IgE produc-
tion,9 and there is growing evidence that CD23mediates transport
of allergens through respiratory and gut epithelial barriers.10,11
Thus far, only parts of the 3-dimensional structure (ie, parts of
the head domain) of CD23 have been analyzed by using
crystallography12 and nuclear magnetic resonance analysis,13
and results were not in full agreement. By means of site-
directed mutagenesis of the head domain and subsequent expres-
sion of the mutants in cells, evidence for involvement of the head
domain in IgE binding was provided.14 These findings were
supported by structural studies that have analyzed the interaction
between an incomplete recombinant CD23 head domain
expressed in Escherichia coli and a recombinant Cε3-Cε4–
comprising subfragment of the Fc part of human IgE.15 One study
observed enhanced IgE binding of CD23 variants containing the
stalk region compared with CD23 variants representing only the281
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HRP: Horseradish peroxidaseMFI: Mean fluorescence intensityN63: Asparagine 63Q63: Glutamine 63head domain,16 and another study observed enhanced IgE binding
of a CD23 variant containing a single amino acid exchange in the
stalk region.17 Both attributed the enhanced IgE binding to the
fact that the stalk region can contribute to IgE binding through ac-
curate formation of CD23 trimers because the current assumption
is that CD23 occurs in trimeric form on the cell surface.
In this study we expressed 4 monomeric folded CD23 variants
in insect cells, the first comprising the full extracellular portion of
CD23, including the stalk and head domain; the second identical
with the first, apart from a single amino acid exchange in the stalk
region abolishing the only N-linked glycosylation site of CD23; a
third representing the full head domain; and a fourth consisting of
a truncated head domain. We were able to directly map hitherto
unknown IgE-binding sites on the stalk region of CD23 and could
show that a non–N-glycosylated monomeric version of CD23
bound IgE much stronger than glycosylated CD23. Furthermore,
we demonstrate that omalizumab, a therapeutic antibody that
inhibits IgE binding to FcεRI, also inhibits IgE binding to CD23.METHODS
Construction and recombinant expression of CD23
derivatives in SF9 insect cells
Four constructs of the human low-affinity IgE receptor FcεRII/CD23
(National Center for Biotechnology Information reference sequence
NP_001993.2) were expressed in insect cells based on synthetic genes.
CD23A represented the full extracellular CD23 protein starting from aspartic
acid 48 to the end of the protein (ie, S321). CD23B was identical to CD23A,
but asparagine 63 (N63) was substituted by a glutamine residue (N63 /
glutamine 63 [Q63]). CD23C represented only the head part of the protein (ie,
frommethionine 150 to serine 321), and CD23D consisted of a small head part
starting at serine 156 (S156) and ending at glutamic acid 298 (E298). Further
description of the expression of CD23 derivatives can be found in theMethods
section in this article’s Online Repository at www.jacionline.org.
A detailed description of purification and biochemical and biophysical
characterization of recombinant CD23 constructs, synthesis of CD23 peptides
and generation of CD23 peptide-specific antibodies, and expression and
purification of human Bet v 1–specific monoclonal IgE can be found in the
Methods section in this article’s Online Repository.Binding experiments with recombinant CD23
derivatives and statistical analysis
Binding of antibodies specific for CD23 peptides and binding of an anti-
CD23 mAb (Isotype M-L233; BD Biosciences, San Jose, Calif) to the CD23
derivatives were tested by using ELISA. A detailed description of the binding
experiments can be found in the Methods section in this article’s Online
Repository.
Statistical analysis of the ELISA results was done by calculating the
Student t test for independent means with the program IBM SPSS Statistics
23.0. Coefficients were considered significant at a P value of less than .05.
A detailed description of binding and inhibition experiments in a cell-based
model and the negative stain electron microscopy methods used can be found
in the Methods section in this article’s Online Repository.CD23 structural calculations and predictions
Relative surface exposures were calculated with the MSMS package18 in
the USCF Chimera package19 and with Gly-X-Gly tripeptides20 as reference
states. Graphic depiction of the CD23 head was rendered with PyMOL
(PyMOL Molecular Graphics System, Version 1.7.4; Schr€odinger, NY). The
structural basis for the calculation and depiction was the PDB model
2H2T.12 The secondary structure prediction was performed with the Psipred
server.21,22RESULTS
Expression and purification of folded and
monomeric CD23 derivatives
Four different CD23 constructs spanning different regions of
CD23 were expressed in SF9 insect cells (Fig 1). Two constructs
(ie, CD23A and CD23B) represented the complete stalk and head
region of CD23 and differed by a single amino acid exchange (ie,
N63 to Q63), which eliminated the only N-linked glycosylation
site of CD23 (Fig 1, A and C). The other 2 constructs represented
the head domain of CD23, for which the 3-dimensional structures
alone (CD23C and CD23D) and in complex with IgE (CD23D)
have been reported (Fig 1).12,13,15 CD23D, for which the structure
in complex with IgE has been reported, comprises amino acids
156 to 298 and lacks 6 amino acids at the N-terminal end
compared with CD23C, as well as 23 amino acids at the C-termi-
nal end (Fig 1). The 4 recombinant CD23 derivatives were ex-
pressed with a C-terminal hexahistidine tag in baculovirus-
infected insect cells as soluble proteins and could be detected
with an anti–his-tag antibody in supernatants from infected cells
(see Fig E1, A, in this article’s Online Repository at www.
jacionline.org). The molecular masses of the expressed and puri-
fied CD23 derivatives observed in SDS-PAGE and after blotting
(Fig 2, A; and see Fig E1, A and B) corresponded to those deter-
mined by using mass spectrometry (MALDI; CD23A,
33.7 kDa; CD23B, 33.4 kDa; CD23C, 24.7 kDa; and CD23D,
16.8 kDa; data not shown). Only CD23A and CD23B appeared
larger (ie, approximately 37 kDa) in SDS-PAGE, which has
been reported earlier (see Fig E1, B).23 Compared with a glycosy-
lated control protein containing 9 N-linked glycosylation sites (ie,
horseradish peroxidase [HRP]), the CD23 derivatives showed
weak reactivity when stained for carbohydrates, with CD23A pro-
ducing the strongest staining of the 4 constructs, indicating that
the mutation of N63 to Q63 has successfully removed the carbo-
hydrates attached to this site. No carbohydrate staining was
observed for a nonglycosylated control protein (ie, soybean
trypsin inhibitor; see Fig E1, C, lane N).
All 4 recombinant CD23 derivatives could be purified (Fig 2,A)
and, when studied by using size exclusion chromatography,
were found to occur in a strictly monomeric form (Fig 2, B).
Circular dichroism analyses revealed that all 4 proteins were
folded (Fig 2, C) and consisted of a mixture of a-helices
(CD23A, 17%; CD23B, 19%; CD23C, 12%; and CD23D,
12%), b-sheets (CD23A, 28%; CD23B, 27%; CD23C, 33%;
and CD23D, 34%), turns (CD23A, 24%; CD23B, 24%; CD23C,
25%; and CD23D, 23%), and unordered parts (CD23A,
CD23B, and CD23D, 31%; CD23C, 30%; data not shown).
Thus we were able to assemble a set of 4 folded and
monomeric CD23 derivatives representing different parts of
CD23, with and without the N-linked glycosylation site for
functional assays.
FIG 1. Overview of CD23 constructs. A, Amino acid sequence of CD23. Indicated are the constructs CD23A,
CD23B, CD23C, and CD23D; peptides (P1-P7) used to raise specific antisera (brown bars); N-linked glycosyl-
ation sites (red letters); and secondary structure and surface exposure (blue bars) of amino acids, as derived
from the crystal structure PDB:2H2T (Wurzburg et al12). A region in which no data are available (R253-E257)
is indicated by a gray bar. Amino acids involved in IgE binding according to Hibbert et al13 and Dhaliwal
et al15 are shown in green and blue, respectively. Residues involved in IgE binding according to both
publications are shown in orange. Cysteine residues involved in disulfide bond formation are numbered.
CD23 domains are shaded (intracellular domain: red; transmembrane domain: yellow; stalk domain: green;
head domain: purple). B, Schematic representation of the known (Wurzburg et al12) and predicted
3-dimensional structure of CD23. CD23 peptides are indicated. Data for region R253-E257, as well as
for the C-terminal end, are not available. C, Sketch of the recombinant CD23 constructs (CD23A,
CD23B, CD23C, and CD23D), as cloned into plasmid pTM1 with a C-terminal hexa-histidine tag (6xHis)
and an N-terminal melittin signal sequence. Amino acids at the N- and C-terminal ends of CD23 and one
mutated in CD23B are indicated in black.
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particular the nonglycosylated CD23B variant show
superior IgE binding
In a first set of experiments, we investigated the binding of IgE
and IgE-allergen immune complexes to the CD23 derivatives. For
this purpose, the CD23 variants were immobilized to ELISA
plates and incubated with a human IgEmAb specific for the major
birch pollen allergen Bet v 1 alone or in complex with Bet v 1 (Fig
3). When IgE (Fig 3, A, left panel) or IgE in complex with Bet v 1
(Fig 3, A, right panel) bound to the CD23 derivatives was detected
with anti-human IgE antibodies, we observed that the CD23
derivatives containing the stalk region (ie, CD23A and CD23B)
bound IgE stronger than the CD23 derivatives without the stalk
region (ie, CD23C and CD23D). Interestingly, the strongest IgE
binding was obtained for CD23B, which had the amino acid
exchange in the N-linked glycosylation site (Fig 3, A).
A similar result was obtained when the bound IgE–Bet v 1
complexes were detected with antibodies specific for the allergen.
As exemplified for CD23A and CD23C, the CD23 construct
containing the stalk region bound the IgE-allergen complexes
much better than the construct containing only the head domain
(Fig 3, B). The latter experiment also confirmed the correct
formation of the IgE-allergen complexes and their binding tothe CD23 derivatives because the complex was detected by
anti–allergen-specific antibodies.
The specificity of IgE binding to the CD23 derivatives was
further investigated by using an anti-CD23 mAb that inhibits IgE
binding to CD23. We found that this antibody, but not an isotype-
matched control antibody, inhibited IgE binding to CD23A and
CD23B (Fig 3, C). Next, we investigated whether omalizumab, a
registered therapeutic anti-human IgE antibody, is able to block
IgE binding to CD23. Using the 4 recombinant CD23 constructs,
we were indeed able to show that preincubation of IgE with
omalizumab inhibited IgE binding to CD23 compared with an
isotype-matched control antibody (Fig 3, D).Mapping of direct IgE binding sites in the CD23
stalk region with peptide-specific antibodies
To investigate the involvement of different portions of CD23 in
IgE binding, we produced a set of synthetic CD23 peptides (see
Table E1 in this article’s Online Repository at www.jacionline.
org) derived from different regions in the CD23 molecule. The
peptides in the CD23 sequence (Fig 1, A) were located in the
transmembrane region (ie, peptide 2) or in the stalk region (ie,
peptides 1 and 4), comprised several portions of the head domain
FIG 2. Biochemical, biophysical, and immunologic characterization of recombinant CD23 constructs.
A, Coomassie-stained gel containing aliquots of purified CD23 constructs. B, Gel filtration profile of the 4
CD23 constructs. Adsorptions at 210 and 280 nm (y-axes, milliabsorbance units [mAU]) recorded during
elution (x-axes, elution volumes in milliliters and corresponding protein size ranges in kilodaltons) are
shown. C, Circular dichroism analysis of the 4 CD23 constructs. An overlay of the 4 circular dichroism
spectra of constructs CD23A to CD23D is shown. CD23A, red; CD23B, pink; CD23C, blue; CD23D, yellow.
X-axis, wavelength [in nanometers]; y-axis, [u]mr (mean-residue molar ellipticity).
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peptide 3). Three shorter versions of peptide 6 (peptides P6a, P6b,
and P6c; see Table E1) were synthesized for direct binding exper-
iments with anti-CD23 antibodies. Peptides 1 to 6 were then used
to immunize rabbits to generate anti-sera that should be capable
of targeting the corresponding sequences in the intact folded
CD23 molecule. In a first set of experiments, the resultant anti-
bodies were used as probes to study surface exposure of certain
portions of CD23. When we tested the anti-peptide antibodiesfor reactivity with the folded CD23 derivatives, we found that
antibodies raised against peptide 2, primarily including the
transmembrane domain, did not bind to the 4 constructs because
the peptide was either not present (ie, CD23C and CD23D) or
only partially represented (ie, CD23A and CD23B) in the CD23
derivatives (see Fig E2 in this article’s Online Repository at
www.jacionline.org). Antibodies raised against peptides 1 and 4
reacted specifically with the constructs containing the stalk region
(ie, CD23A and CD23B) but not with the derivatives lacking the
FIG 3. Binding of IgE to CD23. A, Varying binding of IgE to the CD23 constructs. ELISA plates were coated
with recombinant CD23 constructs A through D or a control protein and incubated with either IgE alone (IgE)
or IgE-Bet v 1 complexes (IgE1Bet v 1). Absorbance values (A 405 nm) corresponding to bound IgE are
indicated on the y-axis. B, Binding of the IgE–Bet v 1 complexes to CD23A and CD23C. For control purposes,
IgE was omitted (Bet v 1 only) or rabbit antibodies without specificity for Bet v 1 (control antibody) were
used. Absorbance values (A 405 nm) corresponding to bound Bet v 1 detected with rabbit anti–Bet v 1
antibodies are indicated on the y-axis. Error bars show SDs of triplicates. C and D, Binding of monoclonal
IgE to recombinant CD23 constructs can be blocked with a-CD23 (Fig 3, C) or omalizumab (Fig 3, D). In Fig 3,
C, ELISA plates with bound CD23A and CD23B were preincubated with a-CD23 (black bars) or with an
isotype control (white bars) and incubated with IgE. In Fig 3, D, IgE was preincubated with omalizumab
(black bars) or an isotype control (white bars) before incubation with CD23 constructs (x-axis: CD23A,
CD23B, CD23C, and CD23D). Absorbance values (A 405 nm) corresponding to bound IgE are indicated on
the y-axis. Error bars show SDs of triplicates. *P < .05 and **P < .01, 2-tailed test.
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only antibodies raised against peptides 6 and 7 from the head
domain, but not peptide 5–specific antibodies, reacted with the
CD23 constructs. Because peptide 5–specific antibodies reacted
with the isolated peptide 5, lack of reactivity is not due to the
failure of obtaining peptide-specific antibodies (data not shown).
Anti-peptide 3 antibodies reacted specifically with each of the
constructs containing the CD23 C-terminal end (ie, CD23A,
CD23B, and CD23C) but not with the construct lacking the
C-terminal end (CD23D, see Fig E2). All constructs were
recognized by the anti-CD23 mAb, which inhibited IgE binding
to CD23 (positive control, see Fig E2).
Next, we investigated whether the anti-CD23 mAb that
inhibited IgE binding to CD23 reacts with the synthetic CD23
derived peptides (see Table E1) and found that this antibody only
reacted with folded CD23 but not with any of the peptides (Fig 4,
A). We then tested whether the peptide-specific antibodies inhibit
binding of the anti-CD23 mAb. We observed a weak inhibition
with anti–peptide 6 antibodies, as well as with a mix of all anti-
peptide antisera or other combinations containing anti–peptide
6 (ie, anti–peptide 1, 4, and 6 antibodies or anti–peptide 1 and 6
antibodies in combination; Fig 4, B). These experiments suggest
that the anti-CD23mAb recognizes an epitope close to the peptide
6 amino acid sequence. Furthermore, it likely binds with higheraffinity to CD23 than the peptide-specific antibodies because
the inhibition by anti–peptide 6 antibodies was weak (ie, 18.5%
inhibition of binding; data not shown).
We then used the peptide-specific antibodies to block IgE
binding to CD23 (Fig 4, C and D). We found that the antibodies
against peptides 1 and 4 from the stalk region inhibited IgE
binding to the CD23A and CD23B variants (Fig 4, C and D).
Inhibitions of IgE binding by antibodies specific for peptide 1
were 29% for CD23A and 39% for CD23B. Peptide 4 antibodies
were able to inhibit IgE binding to CD23A by 20% and to
CD23B by 31% (data not shown). Likewise, antibodies specific
for peptide 6 from the head domain partially inhibited IgE
binding to both CD23 variants (CD23A, 32%; CD23B, 44%;
data not shown), whereas the other peptide antibodies had no
effect on IgE binding. Inhibition of IgE binding to CD23A and
CD23B was also observed with combinations of anti–peptide 1,
4, and 6 (CD23A, 25%; CD23B, 55%; data not shown) and was
even more pronounced when a combination of anti–peptide 1
and 6 antibodies was used (CD23A, 43%; CD23B, 58%; data
not shown; Fig 4, C and D). These experiments show that the
binding of IgE to monomeric CD23 can be inhibited with
antibodies directed against 2 distinct peptides in the CD23 stalk
region, which demonstrate a direct involvement of the stalk
region in IgE binding. Our experiments also confirm that amino
FIG 4. Blocking ability of CD23 peptide-specific antibodies. A, Ability of monoclonal anti-CD23 to bind to
different anti-CD23 peptides. CD23A was used as a positive control. B, Influence of anti-CD23 peptide
antibodies on binding of monoclonal anti-CD23. CD23A was preincubated with anti-peptide antibodies or
the corresponding preimmune sera (x-axis) and then incubated with the anti-CD23 antibody. Absorbance
values (A 405 nm: y-axes) correspond to bound anti-CD23 antibody. Error bars show SEs of at least
triplicates. The experiments were repeated 3 times with similar results. C and D, Influence of anti-CD23
peptide antibodies on the binding of IgE to CD23A (Fig 4, C) and CD23B (Fig 4, D). CD23 constructs were pre-
incubated with anti-peptide antibodies or the corresponding preimmune sera (x-axes) and then incubated
with IgE. Absorbance values (A 405 nm: y-axes) correspond to bound IgE. Error bars show SDs of triplicates.
E, Influence of antibodies on IgE binding to CD23-expressing B cells. Shown is the percentage blocking of
IgE binding (y-axis) to CD23-expressing B cells by an anti-CD23 mAb and by antibodies specific for CD23
peptides (x-axis), as determined by using flow cytometry. Error bars show SDs of triplicates. The
experiment was performed twice with similar results. *P < .05 and **P < .01, 2-tailed test.
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involved in IgE binding (Fig 1, A). Interestingly, anti–peptide 7
antibodies did not inhibit IgE binding to CD23, although this
peptide contained amino acids that were reported to be
directly involved in IgE binding (Fig 1, A).13,15 The lack of
inhibition of IgE binding by anti–peptide 5 antibodies can be
explained by the fact that these antibodies did not react with
folded CD23.
Results obtained for the protein interactions could be confirmed
in cellular experiments. Antibodies specific for peptides 4 and 6inhibited IgE binding to B cells expressing CD23 (Fig 4, E).
A weak inhibition was also obtained with anti–peptide 1
antibodies but not with anti–peptide 7 antibodies (Fig 4, E).Visualization of the trimolecular complex
consisting of CD23A, IgE, and allergen by using
negative stain electron microscopy
Negative stain electron microscopy allows us to directly
visualize the interaction of molecules.24,25 It has been used
FIG 5. Negative stain electron microscopy of recombinant CD23 in complex with IgE and allergen. Shown
are 3 representative negative stain electron microscopy images and interpretive sketches of IgE alone (A),
an anti-His IgG Fab fragment (B), a mix of IgE plus anti-His IgG Fab fragment (C), IgE-CD23 complexes
marked with an anti-His IgG Fab fragment (D), and IgE-CD23-allergen complexes marked with an anti-His
IgG Fab fragment (E). Black bars represent 25 nm.
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FcεRI and an anti-human IgE antibody.26,27 We used CD23A
together with a human IgE mAb specific for the major birch
pollen allergen Bet v 1 and the Bet v 1 allergen to visualize
complexes of the 3 molecules (Fig 5). The challenge regarding
visualization of the interaction of CD23 with IgE and theBet v 1 allergen is that CD23 (33.7 kDa) and Bet v 1 (17 kDa)
are very small molecules compared to IgE (190 kDa). Therefore
we used an anti-His-Fab, which has a size and shape (ie, donut-
like shape) distinct from IgE, to investigate the trimolecular inter-
action. In Fig 5, A, monoclonal Bet v 1–specific IgE alone is
shown. The 3 domains (Fc arm and 2 Fab arms) of the molecules
J ALLERGY CLIN IMMUNOL
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possible. Fig 5, B, shows the donut-shaped anti–His-Fab
fragment by itself. In Fig 5, C, we added the anti–His-Fab
fragment to the IgE preparation. The Fab fragment is not able
to bind to the IgE and is therefore separate from IgE.
However, when CD23Awas added to the preparation, complexes
consisting of 1 IgE molecule and 1 CD23 molecule, as indicated
by the anti–His-Fab, became visible (Fig 5, D). These complexes
were a minority in the preparation; however, they were only seen
when CD23 was added compared to control results. A possible
explanation for the relatively small number of complexes
observed in the mixes could be weak affinity of the IgE-CD23
complex. We then additionally added Bet v 1 allergen to the
anti–His-Fab–CD23–IgE complex and observed an increase of
the size of the previously observed complexes (Fig 5, E).
Interpretation of the samples was challenging because
several possible complexes exist in one sample. In addition to
the anti–His-Fab–CD23–IgE–Bet v 1 complex, IgE–Bet v 1,
IgE–CD23–Bet v 1, anti–His-Fab–CD23–IgE, anti–His-Fab–
CD23, and CD23-IgE complexes are also possible, as well as
each of the added molecules by themselves. However, again,
even though they were a minority, large anti–His-Fab–CD23–
IgE–Bet v 1 complexes could be observed repeatedly and only
in CD23-containing preparations compared to controls. Their
sizes and shapes are best explained by a 1:1 interaction between
CD23 and IgE, indicating that CD23 interacts as a monomer
with IgE in this experimental setup.DISCUSSION
The IgE-CD23 interaction has regained considerable attention
because it contributes to allergic inflammation through IgE-
facilitated allergen presentation to T cells and enhancement of
transepithelial allergen migration.7,10,11 Our analysis of the inter-
action between IgE and CD23 has revealed several novel findings
that can change current concepts of the interaction of these mol-
ecules and in addition might be of relevance for therapeutic ap-
proaches for IgE-associated allergy. We expressed and purified
a set of folded and monomeric CD23 protein derivatives differing
in size and N-linked glycosylation to conduct a series of
functional assays investigating the binding of the trimolecular
complex between CD23, IgE, and a corresponding allergen.
Direct IgE-binding experiments showed that monomeric CD23
containing the stalk region exhibited superior IgE binding
compared with CD23 derivatives without the stalk region, which
indicated a direct involvement of the stalk region in IgE binding.
This finding was unexpected because thus far, it has been thought
that the CD23 stalk region is important for the trimerization of
CD23 and that this trimeric state indirectly enhances IgE binding
to CD23.16,28 However, our data demonstrate that CD23
derivatives containing the stalk region are monomeric and can
bind IgE. According to preliminary plasmon surface resonance
(GE Healthcare Biacore, Uppsala, Sweden) experiments, the
affinity of the monomeric protein to IgE was similar to that
described in earlier studies.13 Further support for a 1:1 binding
of monomeric CD23 to IgE and IgE-allergen complexes came
from negative stain electron microscopy experiments.
Another interesting observation was that a single amino acid
exchange in the only N-linked glycosylation site of CD23
strongly enhanced IgE binding. In fact, it has been reported that
single nucleotide polymorphisms in this region were related to thedevelopment of asthma, and it has been observed that cells
expressing CD23 variants containing an amino acid exchange
close to but not within the N-linked glycosylation site (ie, R62-
W62) showed better IgE binding.17 The authors who made this
observation considered that this exchange might have affected
the trimerization of CD23 on the cell surface and thus might
have caused increased IgE binding. However, our experiments
demonstrate that the exchange directly enhanced the binding of
monomeric CD23 to IgE. The enhancement of IgE binding by
the mutation in the glycosylation site might be due to the removal
of sugar residues hindering IgE binding. Alternatively, it is
possible that mutations of certain critical amino acids might
improve the affinity of CD23 for IgE. Thus it is quite possible
that the binding of IgE to CD23 can be regulated in cells through
point mutations through varying glycosylation and/or altered
affinity. Hence the reported nucleotide polymorphisms in the
DNA encoding the stalk region might directly affect the affinity
for IgE binding and thus result in different susceptibilities for
asthmatic patients. According to this model, atopic patients
expressing less glycosylated CD23 might bind IgE better through
CD23 and, consequently, exhibit more severe forms of allergic
inflammation because CD23 is important for IgE-facilitated
allergen presentation, leading to activation of allergen-specific
T-cell and cytokine responses.
Therefore we tested our hypothesis of a critical and direct stalk
involvement of CD23 in binding its ligand IgE through inhibition
experiments. By using peptide-specific antibodies, binding sites
previously identified by structural studies could be confirmed. For
example, site-directed mutagenesis in the peptide 6 region in the
head domain of CD23 was able to affect IgE binding to the
receptor molecule.14 However, we did not observe a blocking ef-
fect by anti–peptide 7 antibodies, even though certain amino acids
contained in peptide 7 were described to be directly involved in
IgE binding.13,15 Peptide 5–specific antibodies did not bind to
the CD23 constructs. Because these antibodies reacted with the
isolated peptide 5, lack of reactivity is not due to failure of
obtaining peptide-specific antibodies but could be a result of a
lack of surface exposure of the amino acids contained in peptide
5 on the folded CD23 molecules. In fact, according to the
3-dimensional structure determined for the head domain,12
several amino acids included in peptide 5 are not exposed on
the surface of the CD23 molecule. Unlike in peptides 6 and 7,
no exposed segment comprising several contiguous amino acids
can be found in peptide 5 (Fig 1, A). We also noted that certain
amino acids throughout the CD23 head domain (eg, W184,
L198, I221, G222, and A279), which have been described as
contact residues for the IgE interaction,13,15 were not found to
be surface exposed in the 3-dimensional structure determined
for the head domain.12
Importantly, antibodies against peptides 1 and 4, which are
both located in the stalk region, strongly inhibited IgE binding to
CD23 in protein interaction assays and by using cultured cells
expressing CD23. Because the CD23 molecules used in the
molecular inhibition assays represented monomeric proteins, an
indirect involvement of the stalk region by formation of CD23
oligomers with enhanced IgE binding can be excluded. Thus these
experiments unambiguously mapped IgE-binding sites on the
CD23 stalk region.
Taken together, our experimental data with blocking antibodies
identified antibodies against 2 distinct regions in the stalk domain
of CD23, which can shield CD23 from IgE binding. However, it is
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cells abolishes IgE binding,29 and therefore one must assume that
the isolated stalk alone does not bind IgE but rather cooperates
with the head in IgE binding. Nevertheless, our observations point
to a direct and critical involvement of the CD23 stalk domain in
IgE binding and provide a novel view regarding the molecular
mode of IgE binding to CD23.
Using the molecular model of the CD23-IgE interaction, we
made another observation of high clinical relevance. We found
that the therapeutic anti-human IgE antibody omalizumab was
also able to inhibit IgE binding to CD23. In fact, it has been
hypothesized previously that omalizumab, which inhibits binding
of IgE to FcεRI might also affect IgE binding to CD23 and thus
could offer additional benefit to patients through an effect that
goes beyond inhibition of allergen-inducedmast cell and basophil
degranulation, such as IgE-facilitated allergen presentation.6,7,30
Recently, the 3-dimensional structure of the omalizumab Fab
has been determined by using x-ray crystallography.31 Based on
in silico docking experiments, it has been proposed that omalizu-
mab can inhibit IgE binding to CD23,32 but thus far, no definitive
experiments have been performed to investigate this possibility.
Our experiments now unequivocally demonstrate for the first
time in a defined molecular experimental setup that the
therapeutic anti-human IgE antibody omalizumab inhibits
IgE binding to CD23 and thus has the potential to inhibit
CD23-mediated allergic inflammation as well.
In summary, our studies provide a newmolecular model for the
CD23-IgE-allergen interaction and conceivably might open new
doors for the treatment of IgE-associated allergy based on the
interference of this interaction.
Clinical implications: The new interaction model of CD23 and
IgE and its inhibition by omalizumab might open new opportu-
nities for allergy treatment.REFERENCES
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METHODS
Construction and recombinant expression of CD23
derivatives in SF9 insect cells
Each of the 4 constructs contained a C-terminal 6x histidine tag to facilitate
purification. Synthetic genes coding for the constructs were codon optimized
for insect cell expression (GenScript, Piscataway, NJ) and cloned into the
polyhedrin promoter–harboring expression vector pTM1E1 through BamHI
and SmaI sites. DNA sequences and their correct insertion were verified by
using double-strand sequencing with the primers CGCCCAGGACTCTAGC
TATAG (forward) and TGATGATGATGATGATGG (reverse). The melittin
sequence of the pTM1 vector ensures export of the protein into the culture
supernatant, whereby the export sequence is cleaved off, leaving 2 additional
amino acids (aspartic acid and proline) at the N-terminal end of each protein.
For generation of recombinant baculovirus harboring CD23 cDNA and
subsequent expression of the CD23 proteins in SF9 insect cells, the Bac-to-
Bac TOPO expression system (Life Technologies, Carlsbad, Calif) was
used, according to the manufacturer’s protocol.E2 The time course of
expression was monitored in culture supernatants by using Western blotting.
For this purpose, aliquots of the culture supernatants containing CD23
proteins were separated by means of SDS-PAGE and blotted onto a
nitrocellulose membrane (Whatman, Little Chalfont, United Kingdom).
Membranes were blocked with buffer A (Tris-buffered saline containing
0.05%Tween 20) containing 5%wt/vol milk powder (AppliChem, Darmstadt,
Germany) for 1 hour at room temperature, washed 3 times for 10 minutes with
buffer A, and incubated with a 1:4000 in buffer A diluted HRP-labeled
anti–His-tag antibody (Thermo Scientific, Waltham, Mass) for 1 hour at
room temperature. Bound antibodies were visualized by using chemilumines-
cence with an ECL detection kit (Bio-Rad Laboratories, Hercules, Calif) and
exposure of blots to x-ray films (Kodak, Rochester, NY).
Purification and biochemical and biophysical
characterization of recombinant CD23 constructs
Protein-containing culture supernatants were concentrated by using an
Amicon concentration cell (Millipore, Darmstadt, Germany), and recombi-
nant proteins were bound through the His-tag to a Co21-containing column
(ClonTech, Mountain View, Calif), eluted with 150 mmol/L imidazole, and
dialyzed against 10 mmol/LTris (pH 8) containing 100 mmol/L NaCl. Protein
aliquots were stored at2808C. The purity and identity of the recombinant pro-
teins was checked by using SDS-PAGE, followed by Coomassie Blue staining
and by immunoblotting with the anti–His-tag antibody or rabbit anti–peptide 6
antibodies (1:10,000, Table E1). Bound rabbit antibodies were detected with
HRP-labeled goat anti-rabbit antibodies (GE Healthcare, Chalfont St Giles,
United Kingdom) diluted 1:50,000 in buffer and ECL detection. Glycoprotein
staining of an SDS-PAGE gel containing CD23 derivatives was performed
with the Pierce glycoprotein staining kit (Pierce, Waltham, Mass), according
to the manufacturer’s instructions.
Purified CD23 proteins in 10 mmol/L sodium phosphate (pH 7) were used
to acquire mass spectra by using MALDI-TOF (Microflex, Bruker, Billerica,
Mass). To this end, the samplesweremixed at a 1:1 ratiowithmatrix (sinapinic
acid dissolved in 60% acetonitrile and 0.1% trifluoroacetic acid), spotted onto
the target, and air-dried.E2 Folding of the recombinant proteins was analyzed
by using circular dichroism spectroscopy on a Jasco J-810 spectropolarimeter
(Japan Spectroscopic, Tokyo, Japan) with a 1-mm path length cell at room
temperature and a wavelength range from 185 to 260 nm at a resolution of
1 nm at 20 nm/min scanning speed and a 1-second response time.E3 Data of
3 measurements were averaged. The final spectra were baseline corrected,
and results were expressed as the mean-residue molar ellipticity ([u]mr) at a
given wavelength. The secondary structure content of the CD23 derivatives
was calculated by using the secondary structure estimation program
CDSSTRE4 and the reference set 4.E5
Recombinant CD23 constructs were checked for possible aggregation by
means of gel filtration/size exclusion chromatography.E3 Aliquots of 1 mL
containing the different CD23 constructs (250-600 mg/mL in buffer B:
20 mmol/L Tris buffer [pH 7.4] and 150 mmol/L NaCl) were loaded on a
Superdex 200 10/300 GL column (GE Healthcare, Uppsala, Sweden) for gel
filtration. For gel filtration, buffer B was used at a flow rate of 0.5 mL/min
at 48C. Absorbance was monitored at 210 and 280 nm. Gel filtration standard
proteins (Bio-Rad Laboratories: thyroglobulin, 670 kDa; bovine gamma
globulin, 158 kDa; chicken ovalbumin, 44 kDa; equine myoglobin, 17 kDa;
and vitamin B12, 1.35 kDa) were run under similar conditions to determine
the constructs’ size.
Synthesis of CD23 peptides and generation of CD23
peptide-specific antibodies
CD23 peptides (Table E1) were synthesized by using the Fmoc (9 fluorenyl
methoxy carbonyl) strategy with HBTU (2-[1H-benzotriazol-1-yl]1,1,3,3
tetramethyluronium hexafluorophosphate) activation (0.1 mmol small-scale
cycles) on an Applied Biosystems (Foster City, Calif) Peptide Synthesizer
Model 433A, as previously described.E6 Cysteine residues were added to
peptides P1, P2, P3, P4, and P6, as indicated in Table E1, whereas peptides
P5 and P7 contained cysteine residues. The short peptides P6a, P6b, and
P6c were made without modification. Peptides were purified to greater than
90% purity by means of preparative HPLC, and their identity was confirmed
by using mass spectrometry (piChem, Graz, Austria). Antibodies against
KLH-coupled peptides (P1, P2, P3, P4, and P7; maleimide-activated
KLH conjugation kit; Sigma-Aldrich, St Louis, Mo) or Blue Carrier
Protein–coupled peptides (peptides P5 and P6; Imject EDC Blue Carrier
Protein Spin kit, Thermo Scientific) were raised in rabbits (Charles River,
Kisslegg, Germany).E6
Expression and purification of human
Bet v 1–specific monoclonal IgE
Human monoclonal IgE specific for the major birch pollen allergen Bet v 1
was expressed, as previously described.E7 High-yield IgE production was
obtained in a bioreactor (CELLine CL 350; Sartorius, G€ottingen, Germany)
with DMEM high-glucose media (Life Technologies) supplied with 5%
ultralow IgG FBS (Life Technologies). Bet v 1–specific IgE was purified by
using affinity chromatography with an anti-IgE mAb.E8
Binding experiments with recombinant CD23
derivatives and statistical analysis
ELISA plates (Nunc Maxisorp, Roskilde, Denmark) were coated with
recombinant CD23 proteins dissolved in coating buffer (100 mmol/L sodium
carbonate-bicarbonate [pH 9.3], c5 5 mg/mL; 50 mL/well). Plates were then
washed with buffer C (PBS, 0.02% vol/vol Tween 20) and reacted with either
the peptide-specific rabbit antisera and the corresponding preimmune sera as a
control (diluted 1:1000) or with the anti-CD23 antibody (1:1000) and mouse
IgG1 as control overnight at 48C. Plates were again washed with buffer C.
Bound rabbit antibodies were detected with HRP-labeled anti-rabbit IgG
antibodies (GE Healthcare) diluted 1:5000 and ABTS (2,2’-azino-bis[3-
ethylbenzothiazoline-6-sulphonic acid]) as a substrate. Bound mouse anti-
bodies were detected with an HRP-labeled anti-mouse IgG-ECL antibody
(GE Healthcare) diluted 1:5000 and ABTS instead. Results represent means
of triplicate determinations 6 SD after subtraction of background, as
determined with the preimmune sera and isotype control, respectively.
Binding of human IgE and IgE-allergen immune complexes to CD23
derivatives was also investigated by using ELISA experiments. Plates were
coatedwith equimolar amounts of the recombinant CD23 proteins dissolved in
coating buffer (100 mmol/L sodium carbonate-bicarbonate [pH 9.3],
c 5 200 nmol/L; 50 mL/well). Plates were then washed with buffer C (PBS
and 0.02% vol/vol Tween 20). Bet v 1–specific IgE (5 mg/mL in buffer C)
alone or preincubated with rBet v 1 (5 mg/mL in buffer C; Biomay, Vienna,
Austria) for 1 hour at 378C was then added and incubated overnight at 48C.
After washing with buffer C, bound Bet v 1–specific IgE and IgE-allergen
complexes were detected with biotin-labeled anti-human IgE antibodies
(KPL, Gaithersburg, Md) at a dilution of 1:2500 in buffer C and incubated
overnight at 48C. After a further washing step, avidin–alkaline phosphatase
(Sigma-Aldrich, Saint Louis, Mo) was added at a concentration of 1:5000 for
1 hour at room temperature. Plates were washed with buffer C, 4-nitrophenyl
phosphate (Sigma-Aldrich) was added as a substrate, and the color reaction
was read at 405 nm with an ELISA reader (Victor3; PerkinElmer, Waltham,
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Mass). Mean values of triplicate determinations 6 SDs were calculated. In
another set of experiments, bound IgE–Bet v 1 immune complexes were
detected with rabbit anti–Bet v 1 antibodies (1:1000),E9 followed by
HRP-labeled anti-rabbit IgG antibodies (GE Healthcare) diluted 1:5000 and
ABTS as substrate. For control purposes, experiments were performed only
with Bet v 1 without IgE and by using control rabbit antibodies without
specificity for Bet v 1 instead of the rabbit anti–Bet v 1 antibodies.
The specificity of IgE binding to the CD23 derivatives was tested in a series
of ELISA inhibition experiments. First, inhibition of IgE binding was
investigated by preincubating plate-bound CD23 derivatives with the
a-CD23 antibody (Isotype M-L233, BD Biosciences) at a concentration of
5 mg/mL or mouse IgG1 as a negative control for 2 hours at room temperature
before IgE was added. Second, on another set of experiments, IgE was prein-
cubated with 25 mg/mL omalizumab (Xolair; Novartis, Basel, Switzerland) or
an isotype-matched human IgG1 (Sigma-Aldrich) at 378C for 1 hour before
addition to plate-bound CD23 derivatives. Third, the ability of the anti-
CD23 peptide antibodies to inhibit IgE binding to CD23 derivatives was
investigated. For this purpose, plate-bound CD23 derivatives were incubated
with the 1:50 diluted peptide-specific antibodies or the corresponding 1:50
diluted preimmune immunoglobulin for 2 hours at room temperature, washed,
and then incubated with IgE.
We also tested whether the anti-CD23 mAb reacts with the synthetic CD23
peptides. Peptides were coated onto ELISA plates (5mg/mL) and reacted with
the 1:1000 diluted antibody or isotype control. Furthermore, it was studied
whether the peptide-specific antibodies can inhibit binding of the mAb to
CD23A. For this purpose, ELISA plate–coated CD23Awas preincubated with
the peptide-specific antibodies (1:50) or the corresponding preimmunoglobu-
lin, and then binding of the mAb was assessed.
Binding and inhibition experiments in a cell-based
model
EBV-transformed B cells (23 105 per condition) expressing high levels of
CD23E10 were blocked with PBS containing 1% BSA (PAA, Pasching,
Austria) and 10% goat serum (Sigma-Aldrich) for 20 minutes on ice. Then
cells were washed (PBS with 1% wt/vol BSA) and incubated with
peptide-specific rabbit anti-sera or the respective preimmune serum as a
control in a 1:2 dilution for 20 minutes on ice. For control purposes, cells
were incubated with an anti-CD23 antibody (clone M-L233, BD Biosciences)
or the respective isotype control. After washing (PBS and 1% wt/vol BSA),
cells were resuspended in PBS and 1% wt/vol BSA, and complexes of mono-
clonal anti–Bet v 1 IgE (5 mg/ml) and major birch pollen allergen Bet v 1
trimer (5 mg/mL)E3 were added. IgE and Bet v 1 trimers were preincubated
for 1 hour at 378C to ensure complex formation. After another washing
step, cells were incubated with fluorescein isothiocyanate–labeled anti-IgE
(KPL) and the fixable viability dye eFluor 450 (eBioscience, San Diego, Calif)
for 20 minutes on ice. Expression of CD23 was confirmed in each experiment
by staining 1 extra sample with a phycoerythrin-labeled anti-CD23 antibody
(clone EBVCS2, eBioscience) or the respective isotype control, as well as
viability dye. All experiments were performed in duplicates. Flow cytometry
was performed with a FACSCanto II (BD Biosciences). Thirty thousand
events were acquired per sample and analyzed with FlowJo Software
(TreeStar, Ashland, Ore). Mean fluorescence intensity (MFI) was calculated
with FlowJo Software, and MFI of cells stained with fluorescein
isothiocyanate–labeled anti-IgE in the absence of monoclonal anti–Bet v 1
IgE were subtracted as background. The percentage blocking was calculated
according to the following formula:
1002½100=ðMFI preserum2BackgroundÞ 3 ðMFI antipeptide
serum2BackgroundÞ:
Negative stain electron microscopy
Negative stain electron microscopy was performed with purified Bet v
12specific IgE,E7,E8 the purified CD23 constructs, and rBet v 1. Furthermore,
a His-tag–specific Fab fragment was generated to indicate the His-tagged
CD23 constructs. For this purpose, a mouse IgG1 anti-His–specific
antibody (37-2900, Life Technologies) was incubated in digestion
buffer (100 mmol/L Tris [pH 8], 2 mmol/L EDTA, and 25 mmol/L
2-mercaptoethanol) for 2.5 hours at room temperature. Subsequently, the
antibody was incubated with a papain resin (Pierce, Rockford, Ill) overnight
at 378C, and Fab fragments were purified by depleting full antibodies and
Fc fragments with protein A (Pierce). Negative stain of the samples was
done, as previously described.E11 For this purpose, CD23A was buffered in
10mmol/LTris (pH 8), 100mmol/L NaCl, and 2mmol/L CaCl2. The different
molecules (ie, CD23A, IgE, anti–His-Fab, and Bet v 1) were then complexed
in borate-buffered saline (10 mmol/L sodium borate and 150 mmol/L
NaCl [pH 8.2]) at 48C overnight (CD23A, 2 mg/mL; IgE, 3.5 mg/mL;
anti–His-Fab, 2 mg/ml; and Bet v 1, 2 mg/mL). Samples were floated onto a
2-nm carbon layer, stained with 2% uranyl formate (Polysciences Europe,
Eppelheim, Germany), and transferred to a T 600-Cu grid (Ted Pella, Redding,
Calif). Samples were then viewed under an electron microscope (EM-900
TEM; Carl Zeiss, Oberkochen, Germany).
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FIG E1. Expression in insect cells and purification.A, Time course of expression (x-axes) of CD23 constructs,
as detected in nitrocellulose-blotted insect cell supernatants with an anti2His-tag antibody. Molecular
weights are indicated on the y-axes. B and C, Coomassie (Fig E1, B) and glycan (Fig E1, C) staining of purified
constructs (CD23A, CD23B, CD23C, and CD23D), as well as of a nonglycosylated (N) and glycosylated
(P) control protein.
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FIG E2. Binding of rabbit antisera specific for CD23 peptides to recombinant CD23 constructs: A, CD23A;
B, CD23B; C, CD23C; and D, CD23D. CD23 constructs were incubated with anti-CD23 antibodies with
different specificities (x-axes: rabbit anti-CD23 peptide antibodies anti-P1, anti-P2, anti-P3, anti-P4,
anti-P5, anti-P6, and anti-P7; monoclonal anti-CD23 antibody). Absorbance values (A 405 nm: y-axes)
correspond to bound antibodies. Error bars show SDs of triplicates.
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TABLE E1. Characteristics of synthetic CD23 peptides
CD23 peptides Sequence
Theoretical
isoelectric point Amino acid residues
Molecular
weight (Da)
P1 LESHHGDQMAQKSQSTQISQELEELRAEQC 4.68 30 3441.7
P2 CLWAGLLTLLLLWHWDTTQSLKQLEE 4.65 26 3111.7
P3 CPASEGSAESMGPDSRPDPDGRLPTPSAPLHS 4.43 32 3219.5
P4 CLSSFKSQELNERNEASDLLERLREEVTKLR 4.19 31 3694.1
P5 PEKWINFQRKCYYFGKGTKQWVHARYAC 9.71 28 3509.1
P6 CSPEEQDFLTKHASHTGSWIGLRNLDLKGEF 5.39 31 3516.9
P6a SPEEQDFLTKHASHT 5.26 15 1726.8
P6b GSWIGLRNLDLKGEF 6.07 15 1705.0
P6c LTKHASHTGSWIGLRN 11 16 1778.0
P7 NWAPGEPTSTSQGEDCVMMRGSGRWNDAFC 4.32 30 3345.7
Cysteine residues added for carrier coupling are shown in boldface.
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